Glyburide

Generic Name: Glyburide

Brand Names: Diabeta, Glucovance, Glynase, Amglidia

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₈ClN_₃O_₅S

CAS Number: 10238-21-8

Unique Ingredient Identifier: SX6K58TVWC

Background: Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ...

Indication: Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions: Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Low dosE GlibENclamide in Diabetes Part A

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Glibenclamide

First Posted Date: 2016-07-12

Last Posted Date: 2017-05-31

Lead Sponsor: University of Oxford

Target Recruit Count: 16

Registration Number: NCT02830048

Locations: 🇬🇧
Clinical Research Unit, OCDEM, Churchill Hospital, Oxford, Oxfordshire, United Kingdom

The Drug -Drug Interaction of SP2086 and Glyburide

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: SP2086
Drug: Glyburide

First Posted Date: 2016-06-28

Last Posted Date: 2016-06-28

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT02815787

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Glyburide vs Glucovance in the Treatment of GDM

Early Phase 1

Terminated

Conditions: Gestational Diabetes

Interventions: Drug: Glyburide
Drug: Glucovance

First Posted Date: 2016-04-01

Last Posted Date: 2020-10-12

Lead Sponsor: Texas Tech University Health Sciences Center, El Paso

Target Recruit Count: 7

Registration Number: NCT02726490

Locations: 🇺🇸
TTUHSC El Paso, El Paso, Texas, United States

Spinal Cord Injury Neuroprotection With Glyburide

Phase 1

Terminated

Conditions: Acute Spinal Cord Injury

Interventions: Drug: Glyburide

First Posted Date: 2015-08-14

Last Posted Date: 2022-07-05

Lead Sponsor: Ohio State University

Target Recruit Count: 3

Registration Number: NCT02524379

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

Phase 1

Terminated

Conditions: Cerebral Edema
Brain Metastases

Interventions: Drug: Glyburide
Other: Placebo

First Posted Date: 2015-06-03

Last Posted Date: 2022-09-21

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 1

Registration Number: NCT02460874

Locations: 🇺🇸
University of Alabama at Birmingham (UAB) Department of Radiation Oncology, Birmingham, Alabama, United States

Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Phase 3

Completed

Conditions: Neonatal Diabetes Secondary to Mutation in the Potassium Channel

Interventions: Drug: Glibenclamide

First Posted Date: 2015-03-03

Last Posted Date: 2019-08-30

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 10

Registration Number: NCT02375828

Locations: 🇫🇷
Hôpital Universitaire Necker Enfants Malades, Paris, France

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin
Drug: Glibenclamide

First Posted Date: 2014-12-17

Last Posted Date: 2018-08-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 53

Registration Number: NCT02318693

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Phase 4

Completed

Conditions: Diabetes

Interventions: Drug: Gliclazide
Drug: Glibenclamide

First Posted Date: 2014-07-28

Last Posted Date: 2016-09-01

Lead Sponsor: Khoo Teck Puat Hospital

Target Recruit Count: 8

Registration Number: NCT02201602

Locations: 🇸🇬
Khoo Teck Puat Hospital, Singapore, Singapore

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1356
Drug: Glyburide
Drug: BI 1356 + Glyburide

First Posted Date: 2014-07-08

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02183428

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Hypertension
Endothelial Dysfunction

Interventions: Drug: Vildagliptin
Drug: Glibenclamide

First Posted Date: 2014-05-23

Last Posted Date: 2016-08-16

Lead Sponsor: Dr. José Fernando Vilela-Martin MD PhD

Target Recruit Count: 50

Registration Number: NCT02145611

Locations: 🇧🇷
Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy